293 related articles for article (PubMed ID: 21586099)
1. Therapeutic targets for bone metastases in breast cancer.
Clézardin P
Breast Cancer Res; 2011 Apr; 13(2):207. PubMed ID: 21586099
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapies in bone metastasis.
Clément-Demange L; Clézardin P
Curr Opin Pharmacol; 2015 Jun; 22():79-86. PubMed ID: 25935860
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapies in breast cancer bone metastases.
Clézardin P
Curr Pharm Des; 2010; 16(11):1260-1. PubMed ID: 20298163
[No Abstract] [Full Text] [Related]
4. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of breast cancer metastases to bone.
Guise TA; Kozlow WM; Heras-Herzig A; Padalecki SS; Yin JJ; Chirgwin JM
Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S46-53. PubMed ID: 15807924
[TBL] [Abstract][Full Text] [Related]
6. Future directions of bone-targeted therapy for metastatic breast cancer.
Onishi T; Hayashi N; Theriault RL; Hortobagyi GN; Ueno NT
Nat Rev Clin Oncol; 2010 Nov; 7(11):641-51. PubMed ID: 20808302
[TBL] [Abstract][Full Text] [Related]
7. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Trinkaus M; Ooi WS; Amir E; Popovic S; Kalina M; Kahn H; Singh G; Gainford MC; Clemons M
Oncol Rep; 2009 May; 21(5):1153-9. PubMed ID: 19360288
[TBL] [Abstract][Full Text] [Related]
8. Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.
Hiraga T
Expert Opin Investig Drugs; 2016; 25(3):319-34. PubMed ID: 26778342
[TBL] [Abstract][Full Text] [Related]
9. Bone metastases in the era of targeted treatments: insights from molecular biology.
Dewulf J; Vangestel C; Verhoeven Y; van Dam P; Elvas F; Van den Wyngaert T; Clézardin P
Q J Nucl Med Mol Imaging; 2019 Jun; 63(2):98-111. PubMed ID: 31298015
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer metastasis to the bone: mechanisms of bone loss.
Chen YC; Sosnoski DM; Mastro AM
Breast Cancer Res; 2010; 12(6):215. PubMed ID: 21176175
[TBL] [Abstract][Full Text] [Related]
11. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.
Guise TA; Mohammad KS; Clines G; Stebbins EG; Wong DH; Higgins LS; Vessella R; Corey E; Padalecki S; Suva L; Chirgwin JM
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6213s-6216s. PubMed ID: 17062703
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
Whang YM; Jung SP; Kim MK; Chang IH; Park SI
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
[TBL] [Abstract][Full Text] [Related]
13. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
15. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
Vessella RL; Corey E
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin K inhibitors as treatment of bone metastasis.
Le Gall C; Bonnelye E; Clézardin P
Curr Opin Support Palliat Care; 2008 Sep; 2(3):218-22. PubMed ID: 18685424
[TBL] [Abstract][Full Text] [Related]
17. Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.
Ross MH; Esser AK; Fox GC; Schmieder AH; Yang X; Hu G; Pan D; Su X; Xu Y; Novack DV; Walsh T; Colditz GA; Lukaszewicz GH; Cordell E; Novack J; Fitzpatrick JAJ; Waning DL; Mohammad KS; Guise TA; Lanza GM; Weilbaecher KN
Cancer Res; 2017 Nov; 77(22):6299-6312. PubMed ID: 28855208
[TBL] [Abstract][Full Text] [Related]
18. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation.
Mercer RR; Miyasaka C; Mastro AM
Clin Exp Metastasis; 2004; 21(5):427-35. PubMed ID: 15672867
[TBL] [Abstract][Full Text] [Related]
19. Bone metabolism regulation: Implications for the treatment of bone diseases.
Yao D; Huang L; Ke J; Zhang M; Xiao Q; Zhu X
Biomed Pharmacother; 2020 Sep; 129():110494. PubMed ID: 32887023
[TBL] [Abstract][Full Text] [Related]
20. Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
Suvannasankha A; Chirgwin JM
Breast Cancer Res; 2014; 16(6):484. PubMed ID: 25757219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
